Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jun 6;26(1):119.
doi: 10.1186/s40360-025-00950-y.

Effect of adding fenofibrate versus curcumin to glimepiride in patients with type 2 diabetes: a randomized controlled trial

Eman M Nada  1 , Nashwa M El-Gharbawy  2 , Haidy Abbas  3 , Rehab H Werida  4
Affiliations
Clinical Trial

Effect of adding fenofibrate versus curcumin to glimepiride in patients with type 2 diabetes: a randomized controlled trial

Eman M Nada et al. BMC Pharmacol Toxicol. .

Abstract

Background: Type 2 diabetes is a recognized risk factor for the development of cardiovascular disease. Fenofibrate and curcumin were found to be effective in improving hyperlipidemia in patients with diabetes. This study aimed to evaluate the effect of adding fenofibrate versus curcumin on weight, glycemic status, lipids profile, high-sensitivity C-reactive protein (hs-CRP), fetuin-A, and sirtuin 1 in patients with type 2 diabetes treated with glimepiride.

Method: In a double-blind, randomized control trial, 60 patients with type 2 diabetes mellitus were randomly assigned into three groups: Group I was given placebo; Group II curcumin 1100 mg; Group III fenofibrate 160 mg (each administered orally once daily) to ongoing glimepiride 4 mg therapy administered orally once daily for three months. Inclusion criteria were as follows: patients aged 35-70 years, those with uncontrolled type 2 diabetes, hyperlipidemia, and those treated with glimepiride 4 mg. Exclusion criteria were as follows: other types of diabetes, pregnancy, abnormal liver or kidney function tests, using other anti-diabetes medications, and non-adherence to medications. At baseline and after three months of intervention, anthropometric measurements were measured, and blood samples were collected for biochemical analysis of blood glucose, glycated hemoglobin (HbA1c), lipid profile, hs-CRP, fetuin-A, and sirtuin 1. Paired t-test and one-way ANOVA were used for normally distributed data. However, the Wilcoxon signed-rank and the Kruskal-Wallis tests were used to analyze non-normally distributed data.

Results: Three months after the intervention, when the three groups were compared, no significant differences were found regarding weight, body mass index, fasting blood glucose, two-hour postprandial glucose (2 h-PPG), and HbA1c (p > 0.05). Compared to placebo, significant decreases were observed in total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), very-low-density lipoprotein cholesterol (VLDL-C), coronary risk index (CRI), atherogenic index (AI), and hs-CRP and increasing sirtuin 1 in the fenofibrate (p < 0.001) and curcumin (p < 0.05) groups. High-density lipoprotein cholesterol (HDL-C) levels in the fenofibrate group were found to be significantly higher than in the placebo group (p < 0.001). Furthermore, when compared to curcumin, fenofibrate significantly reduced waist circumferences and fetuin-A and increased sirtuin 1 (p < 0.05).

Conclusion: Both fenofibrate and curcumin are effective at decreasing lipid profiles and improving inflammatory markers in patients with type 2 diabetes. Fenofibrate might have a superior effect in reducing waist circumference, decreasing fetuin-A, and increasing sirtuin 1.

Trial registration: This trial was registered (August 27, 2020) on clinical trial.gov with an identification code NCT04528212. https://www.

Clinicaltrials: gov/study/NCT04528212 .

Keywords: Curcumin; Fenofibrate; Fetuin-A; Hs-CRP; Sirtuin 1; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Ethical approval for the trial was obtained from the Research Ethics Committee, Faculty of pharmacy, Damanhour University, Damanhour, Egypt (with code no.420PP24). Furthermore, this study has been performed following the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Written informed consent was taken from the patients before the study. Consent for publication: Not applicable. Competing interests: No conflict of interest was reported by the authors.

Figures

Fig. 1
Fig. 1
Consort flow diagram for participants’ enrollment, allocation, and follow-up
Fig. 2
Fig. 2
Correlation between levels of fetuin-A and sirtuin-1 after three months of treatment in the studied population and the correlation in each group. A Placebo group, B Curcumin group, C Fenofibrate group, D The three studied groups
See this image and copyright information in PMC

References

    1. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium 2021.
    1. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J.Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Global Health. 2020;10(1):107–11. - DOI - PMC - PubMed
    1. Vijayaraghavan K. Treatment of dyslipidemia in patients with type 2 diabetes. Lipids Health Dis. 2010;9:144. - DOI - PMC - PubMed
    1. Pivari F, Mingione A, Brasacchio C, Soldati L.Curcumin and Type 2 Diabetes Mellitus: prevention and Treatment. Nutrients. 2019;11(8):1837. - DOI - PMC - PubMed
    1. Einarson TR, Acs A, Ludwig C, Panton UH.Economic burden of cardiovascular disease in type 2 diabetes: a systematic review. Value Health. 2018;21(7):881–90. - DOI - PubMed

Publication types

MeSH terms

Associated data